65,437 trials
Rheumatoid Arthritis
Primary: Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs of Special Interest (AESIs) — 14.1; 2.8; 4.2 percentage of participants
Type 2 Diabetes
Primary: Change From Baseline to Week 24 in HbA1c — -0.82; -0.42 percentage of hemoglobin — p=<0.0001
Upper Respiratory Infection
Primary: Nasal Secretion Weights — 3.5; 4.2; 1.2; 2.6 grams
Seizure · Epilepsy · Cerebral Malaria
Primary: Freedom From Seizure — 7 individuals
Chronic Kidney Disease
Primary: Percent Change in Serum LDL-cholesterol Levels From Week 16 to Week 20 (LOCF) (ITT2) — 4.03; 42.55; 2.76; 49.84 Percent Change of LDL-cholesterol
Back Pain
Primary: The Roland Morris Disability Questionnaire (RDQ) Score — 8.3; 6.6 units on a scale
Unilateral Hearing Loss
Primary: Incidence of Device- and Procedure-related Adverse Events at 30 Days — 0 participants
Rheumatoid Arthritis
Primary: Percentage of Participants Who Achieved Remission by Disease Activity Score 28 Based on C-reactive Protein (DAS28-CRP) Criteria at Month 12 and at Both Months 12 and 18…
Veterans' Disability Claims
Primary: Days of Work and Work-related Activity — 8.3; 8.7; 6.6; 9.0 days
Metabolic Syndrome · Bipolar Depression · Insulin Resistance
Primary: Change in the Inventory of Depressive Symptomatology-Clinician Rated (IDS-CR) Score — -16.5 units on a scale
Depressive Disorder, Major · Metabolic Syndrome X
Primary: Change in Depression Symptom Severity From Baseline to Study Endpoint — -20.9 Units on a scale
Hepatocellular Injury · Blood Loss
Primary: Hepatocellular Damage Reflected by Liver Fatty-acid Binding Protein (L-FABP) Levels — 9097; 11,688 ng*h/mL
Dizziness
Primary: Dynamic Gait Index — 18.9; 18.9; 14.2; 16.1 units on a scale — p=0.026
Multiple Myeloma
Primary: Number of Participants With Successful Engraftment at Day 100 — 27; 23 participants
Substance Abuse · HIV Infections
Primary: Feasibility: Proportion of Persons Screened Who Are Eligible and Enrolled — 30 Eligible persons screened who enrolled